RE:Phase II Bladder Cancer Clinical Study (Pivotal) Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, "Another milestone has been reached by the Company with the addition of MU in Pennsylvania as a clinical study site. Theralase is focused on its target of enrolling and treating 11 additional patients in early 2021 for a total of 25 patients for potential Breakthrough Designation Approval and approximately 100 patients in 2021 / 2022." https://www.accesswire.com/625524/Theralase-Launches-Third-Clinical-Study-Site-in-the-US-for-Phase-II-Bladder-Cancer-Clinical-Study
University Health Network (“UHN”) Toronto, Ontario
London Health Sciences Centre (“LHSC”) London, Ontario
Nova Scotia Health Authority (“NSHA”) Halifax, Nova Scotia
University of British Columbia (“UBC”) Vancouver, British Columbia
McGill University Health Centre (“MUHC”) Montreal, Quebec
Virginia Urology (“VU”) Richmond, Virginia
Urology Associates P.C. (“UA”) Nashville, Tennessee
MidLantic Urology (“MU”) Bala Cynwyd, Pennsylvania
Carolina Urolologic Research Centre (“CURC”) Myrtle Beach, SC
[/quote]